Literature DB >> 23772629

Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Nichole R Klatt1, Nicolas Chomont, Daniel C Douek, Steven G Deeks.   

Abstract

Despite complete or near-complete suppression of human immunodeficiency virus (HIV) replication with combination antiretroviral therapy, both HIV and chronic inflammation/immune dysfunction persist indefinitely. Untangling the association between the virus and the host immune environment during therapy might lead to novel interventions aimed at either curing the infection or preventing the development of inflammation-associated end-organ disease. Chronic inflammation and immune dysfunction might lead to HIV persistence by causing virus production, generating new target cells, enabling infecting of activated and resting target cells, altering the migration patterns of susceptible target cells, increasing the proliferation of infected cells, and preventing normal HIV-specific clearance mechanisms from function. Chronic HIV production or replication might contribute to persistent inflammation and immune dysfunction. The rapidly evolving data on these issues strongly suggest that a vicious cycle might exist in which HIV persistence causes inflammation that in turn contributes to HIV persistence.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23772629      PMCID: PMC3694608          DOI: 10.1111/imr.12065

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  237 in total

1.  Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy.

Authors:  Duncan Chege; Prameet M Sheth; Taylor Kain; Connie J Kim; Colin Kovacs; Mona Loutfy; Roberta Halpenny; Gabor Kandel; Tae-Wook Chun; Mario Ostrowski; Rupert Kaul
Journal:  AIDS       Date:  2011-03-27       Impact factor: 4.177

2.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

3.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Authors:  Hiroyu Hatano; Timothy L Hayes; Viktor Dahl; Elizabeth Sinclair; Tzong-Hae Lee; Rebecca Hoh; Harry Lampiris; Peter W Hunt; Sarah Palmer; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Barbara L Shacklett; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

4.  HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.

Authors:  Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Tzong-Hae Lee; Michael P Busch; Jeffrey N Martin; Joseph M McCune; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2011-01-18       Impact factor: 9.079

Review 5.  Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.

Authors:  Gregor F Lichtfuss; Jennifer Hoy; Reena Rajasuriar; Marit Kramski; Suzanne M Crowe; Sharon R Lewin
Journal:  Biomark Med       Date:  2011-04       Impact factor: 2.851

6.  Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections.

Authors:  Ming Zeng; Anthony J Smith; Stephen W Wietgrefe; Peter J Southern; Timothy W Schacker; Cavan S Reilly; Jacob D Estes; Gregory F Burton; Guido Silvestri; Jeffrey D Lifson; John V Carlis; Ashley T Haase
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

Review 7.  Control of epithelial cell function by interleukin-22-producing RORγt+ innate lymphoid cells.

Authors:  Stephanie L Sanos; Cedric Vonarbourg; Arthur Mortha; Andreas Diefenbach
Journal:  Immunology       Date:  2011-04       Impact factor: 7.397

8.  Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques.

Authors:  Nichole R Klatt; Lauren A Canary; Xiaoyong Sun; Carol L Vinton; Nicholas T Funderburg; David R Morcock; Mariam Quiñones; Clayton B Deming; Molly Perkins; Daria J Hazuda; Michael D Miller; Michael M Lederman; Julie A Segre; Jeffrey D Lifson; Elias K Haddad; Jacob D Estes; Jason M Brenchley
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

9.  Impact of highly active antiretroviral therapy initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa.

Authors:  Timothy L Hayes; David M Asmuth; J William Critchfield; Thomas H Knight; Bridget E McLaughlin; Tammy Yotter; Delandy H McConnell; Juan Carlos Garcia; Richard B Pollard; Barbara L Shacklett
Journal:  AIDS       Date:  2013-03-27       Impact factor: 4.177

10.  Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells.

Authors:  Hiroyu Hatano; Vivek Jain; Peter W Hunt; Tzong-Hae Lee; Elizabeth Sinclair; Tri D Do; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; Frederick Hecht; Michael P Busch; Steven G Deeks
Journal:  J Infect Dis       Date:  2012-10-22       Impact factor: 5.226

View more
  179 in total

Review 1.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 2.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

3.  Immune activation, HIV persistence, and the cure.

Authors:  Daniel C Douek
Journal:  Top Antivir Med       Date:  2013 Sep-Oct

4.  Dendritic Cells Enhance HIV Infection of Memory CD4(+) T Cells in Human Lymphoid Tissues.

Authors:  Angel L Reyes-Rodriguez; Morgan A Reuter; David McDonald
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

5.  Predict disease progression from T-cell phenotypes in northern pig-tailed macaques (Macaca leonina) during SIVmac239 infection.

Authors:  Ming-Xu Zhang; Hong-Yi Zheng; Jin Jiang; Jia-Hao Song; Min Chen; Yu Xiao; Xiao-Dong Lian; Tian-Zhang Song; Ren-Rong Tian; Wei Pang; Yong-Tang Zheng
Journal:  Immunology       Date:  2017-08-14       Impact factor: 7.397

6.  Intestinal CD4 Depletion in HIV / SIV Infection.

Authors:  Ronald S Veazey
Journal:  Curr Immunol Rev       Date:  2019

7.  Is successful HIV therapy a Pyrrhic victory for the brain?

Authors:  David B Clifford
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

8.  Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention.

Authors:  Jordan K Kyongo; Tania Crucitti; Joris Menten; Liselotte Hardy; Piet Cools; Johan Michiels; Sinead Delany-Moretlwe; Mary Mwaura; Gilles Ndayisaba; Sarah Joseph; Raina Fichorova; Janneke van de Wijgert; Guido Vanham; Kevin K Ariën; Vicky Jespers
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

9.  Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation.

Authors:  Thibaut Davy-Mendez; Sonia Napravnik; Oksana Zakharova; JoAnn Kuruc; Cynthia Gay; Charles B Hicks; Kara S Mcgee; Joseph J Eron
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-01       Impact factor: 3.731

10.  The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?

Authors:  Steven G Deeks; Pamela M Odorizzi; Rafick-Pierre Sekaly
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.